DUSP9 and hepatocellular carcinoma: Genome-wide CRISPR/Cas9 library screening identified loss of neurofibromin 1 (NF1) and dual specificity phosphatase 9 (DUSP9) as potential regulators of lenvatinib resistance in HCC cells [46].